Literature DB >> 26789514

Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels--The ABC Method.

Yasuharu Yamaguchi1, Yasuhiko Nagata, Ryuuta Hiratsuka, Yoshihiko Kawase, Tatsurou Tominaga, Shunji Takeuchi, Shinya Sakagami, Shusei Ishida.   

Abstract

BACKGROUND: Helicobacter pylori (Hp) infection and gastric atrophy are both risk factors for gastric cancer. Recently it has been found that X-ray examination for gastric cancer screening does not have much effect on the detection rate for gastric cancer in Japan. A candidate for a new mass screening for gastric cancer, the ABC method, using the combination assay of Hp and serum pepsinogen, was useful for identifying the development of gastric cancer in high-risk and low-risk populations. People with higher cancer risk are recommended to receive endoscopy. The ABC method was carried out as a gastric cancer mass-screening on the initiative of Nishitokyo Medical Association in Nishitokyo city from 2011. This paper reviewed the present status of gastric cancer screening using the ABC method, including the latest results of our ongoing screening.
SUMMARY: We report results for 36,627 individuals from 2011 to 2013. Among them, 16,965 received blood examination for the ABC method. Of those, 8,083 planned to undergo endoscopic examination according to stratification of the risk for the development of gastric cancer. In fact, a total of 2,911 individuals underwent endoscopic examination. Gastric cancer was detected in 65 patients, including 52 (80%) diagnosed with early gastric cancer. The ABC method was not organized screening but opportunistic screening. X-ray examination was the organized screening that was ongoing during the same period. Detection cost for 1 gastric cancer case using the ABC method was cheaper than the conventional X-ray screening method (¥1,267,452 vs. ¥2,807,763). KEY MESSAGES: Although further large epidemiological studies are required, the ABC method might be positioned as an effective mass screening for gastric cancer.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26789514     DOI: 10.1159/000441742

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  23 in total

1.  Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan.

Authors:  Shota Saito; Motoi Azumi; Yusuke Muneoka; Katsuhiko Nishino; Takashi Ishikawa; Yuichi Sato; Shuji Terai; Kouhei Akazawa
Journal:  Eur J Health Econ       Date:  2017-05-26

2.  Serum pepsinogen levels indicate the requirement of upper gastrointestinal endoscopy among Group A subjects of ABC classification: a multicenter study.

Authors:  Daisuke Chinda; Tadashi Shimoyama; Tatsuya Mikami; Tetsu Arai; Daisuke Chiba; Yoshio Sasaki; Kazuo Komai; Yoshihiko Sawada; Yoshiharu Saito; Hironobu Chiba; Shinsaku Fukuda
Journal:  J Gastroenterol       Date:  2018-01-20       Impact factor: 7.527

3.  British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.

Authors:  Matthew Banks; David Graham; Marnix Jansen; Takuji Gotoda; Sergio Coda; Massimiliano di Pietro; Noriya Uedo; Pradeep Bhandari; D Mark Pritchard; Ernst J Kuipers; Manuel Rodriguez-Justo; Marco R Novelli; Krish Ragunath; Neil Shepherd; Mario Dinis-Ribeiro
Journal:  Gut       Date:  2019-07-05       Impact factor: 23.059

4.  Classifying risk level of gastric cancer: Evaluation of questionnaire-based prediction model.

Authors:  Maomao Cao; He Li; Dianqin Sun; Lin Lei; Jiansong Ren; Jufang Shi; Ni Li; Ji Peng; Wanqing Chen
Journal:  Chin J Cancer Res       Date:  2020-10-31       Impact factor: 5.087

5.  Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data.

Authors:  Haejin In; Srawani Sarkar; Jessica Ward; Patricia Friedmann; Michael Parides; Julie Yang; Meira Epplein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-07-01       Impact factor: 4.090

6.  Use of Metabolomics as a Complementary Omic Approach to Implement Risk Criteria for First-Degree Relatives of Gastric Cancer Patients.

Authors:  Giuseppe Corona; Renato Cannizzaro; Gianmaria Miolo; Laura Caggiari; Mariangela De Zorzi; Ombretta Repetto; Agostino Steffan; Valli De Re
Journal:  Int J Mol Sci       Date:  2018-03-07       Impact factor: 5.923

7.  Preliminary study of automatic gastric cancer risk classification from photofluorography.

Authors:  Ren Togo; Kenta Ishihara; Katsuhiro Mabe; Harufumi Oizumi; Takahiro Ogawa; Mototsugu Kato; Naoya Sakamoto; Shigemi Nakajima; Masahiro Asaka; Miki Haseyama
Journal:  World J Gastrointest Oncol       Date:  2018-02-15

Review 8.  Gastric Cancer Screening by Combined Determination of Serum Helicobacter pylori Antibody and Pepsinogen Concentrations: ABC Method for Gastric Cancer Screening.

Authors:  Xian-Zhe Chen; Cheng-Zhi Huang; Wei-Xian Hu; Ying Liu; Xue-Qing Yao
Journal:  Chin Med J (Engl)       Date:  2018-05-20       Impact factor: 2.628

9.  Application of data mining methods to improve screening for the risk of early gastric cancer.

Authors:  Mi-Mi Liu; Li Wen; Yong-Jia Liu; Qiao Cai; Li-Ting Li; Yong-Ming Cai
Journal:  BMC Med Inform Decis Mak       Date:  2018-12-07       Impact factor: 2.796

10.  Endoscopic submucosal dissection for the diagnosis and therapy of pedunculated gastric cancer with prolapse into the duodenal bulb: A case report.

Authors:  Norihiko Suzuki; Masashi Yoshida; Hironori Ohdaira; Tomonori Imakita; Nobuhiro Tsutsui; Yasunobu Kobayashi; Junji Takahashi; Shinya Okada; Masaki Kitajima; Yutaka Suzuki
Journal:  Int J Surg Case Rep       Date:  2018-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.